Immunohistochemical assessment of protein phosphorylation state: the dream and the reality.
The development of phosphorylation state-specific antibodies (PSSAs) in the 1980s, and their subsequent proliferation promised to enable in situ analysis of the activation states of complex intracellular signaling networks. The extent to which this promise has been fulfilled is the topic of this review. I review some applications of PSSAs primarily in the assessment of solid tumor signaling pathway activation status. PSSAs have received considerable attention for their potential to reveal cell type-specific activation status, provide added prognostic information, aid in the prediction of response to therapy, and most recently, demonstrate the efficacy of kinase-targeted chemotherapies. However, despite some successes, many studies have failed to demonstrate added value of PSSAs over general antibody immunohistochemistry. Moreover, there is still a large degree of uncertainty about the interpretation of complex and heterogeneous staining patterns in tissue samples and their relationship to the actual phosphorylation states in vivo. The next phase of translational research in applications of PSSAs will entail the hard work of antibody validation, gathering of detailed information about epitope-specific lability, and implementation of methods for standardization.
Mandell
James W
JW
Department of Pathology, University of Virginia School of Medicine, PO Box 800904, Charlottesville, VA 22908, USA. jwm2m@virginia.edu
D000818:Animals; D000918:Antibody Specificity / Q000276:immunology; D015415:Biomarkers; D000939:Epitopes / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry; D010766:Phosphorylation; D011506:Proteins / Q000032:analysis* / Q000276:immunology* / Q000378:metabolism
D015415:Biomarkers; D000939:Epitopes; D011506:Proteins